By Chris Wack
Trevi Therapeutics shares were up 72% at $4.27 after the company said it saw had a positive outcome from the planned sample size re-estimation for its ongoing Phase 2b trial in idiopathic pulmonary fibrosis patients with chronic cough.
Shares in the New Haven, Conn., company hit their 52-week high of $4.50 earlier in the session, and are up 222% in the past 12 months.
The clinical-stage biopharmaceutical company said it doesn't require any changes to the current sample size for the trial.
The trial has reached 75% of the targeted enrollment, and topline results from the full trial continue to be expected in the first half of 2025.
The analysis was conducted on the highest dose in the trial after 50% of the initial targeted trial enrollment, or 80 patients, completed the six weeks of treatment. Based on the analysis, it was recommended that the trial should continue as planned to maintain the pre-specified conditional power of 80% or greater.
The primary efficacy endpoint for the trial is the relative change in 24-hour cough frequency at the end of week six versus baseline. The trial will also explore secondary endpoints, including patient reported outcome measures for cough.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 12, 2024 10:17 ET (15:17 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.